Vytrus Biotech S.A. Asset Resilience Ratio

Latest as of December 2025: 0.00%

Vytrus Biotech S.A. asset resilience ratio. Vytrus Biotech S.A. (VYT) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Vytrus Biotech S.A. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€600.00
≈ $701.46 USD Cash + Short-term Investments

Total Assets

€14.66 Million
≈ $17.14 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Vytrus Biotech S.A. (2020–2025)

Asset resilience ratio of Vytrus Biotech S.A. from 2020 to 2025. This chart shows how Vytrus Biotech S.A.'s Asset Resilience Ratio has changed over time. Read Vytrus Biotech S.A. debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Vytrus Biotech S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Vytrus Biotech S.A..

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €600.00 0.0%
Total Liquid Assets €600.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: Vytrus Biotech S.A. maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Vytrus Biotech S.A. Industry Peers by Asset Resilience Ratio

Compare Vytrus Biotech S.A.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Samsung Biologics Co Ltd
KO:207940
Biotechnology 15.21%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
Biotechnology 5.07%
Immunovant Inc
NASDAQ:IMVT
Biotechnology 98.50%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Amicus Therapeutics Inc
NASDAQ:FOLD
Biotechnology 8.37%

Vytrus Biotech S.A. Asset Resilience Ratio by Year (2020–2025)

Vytrus Biotech S.A. asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Vytrus Biotech S.A..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.00% €600.00
≈ $701.46
€14.66 Million
≈ $17.14 Million
0.00pp
2024-12-31 0.01% €600.00
≈ $701.46
€11.13 Million
≈ $13.01 Million
0.00pp
2023-12-31 0.01% €600.00
≈ $701.46
€9.31 Million
≈ $10.89 Million
0.00pp
2021-12-31 0.01% €520.00
≈ $607.93
€7.18 Million
≈ $8.40 Million
0.00pp
2020-12-31 0.01% €740.00
≈ $865.14
€6.21 Million
≈ $7.26 Million
--
pp = percentage points

About Vytrus Biotech S.A.

MC:VYT Spain Biotechnology
Market Cap
$120.39 Million
€102.98 Million EUR
Market Cap Rank
#18250 Global
#124 in Spain
Share Price
€13.70
Change (1 day)
-2.49%
52-Week Range
€6.70 - €19.80
All Time High
€19.80
About

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more